

# Differential Expression and Phosphorylation of BTK Protein Domain in X-linked Agammaglobulinemia

Mahsa Sohani<sup>1</sup>¥, Samaneh Delavari<sup>1</sup>¥, Amir Hassan Zarnani<sup>2</sup>, Leila Parvaneh<sup>1</sup>, Shima Rasouli<sup>3</sup>, Sepideh shahkarami<sup>1,4</sup>, Sepideh Babaie<sup>2</sup>, Fatemeh Kiaee\*<sup>1,3</sup>

Received: 19 April 2019/ Accepted: 24 May 2019/ Published online: 22 June 2019

## Abstract

**Introduction:** X-linked (Bruton's) agammaglobulinemia (XLA) is a rare congenital disorder with defects in early B cell development caused by mutations in the gene encoding BTK (Bruton tyrosine kinase). The aim of this study was to investigate the expression and phosphorylation of BTK protein domain in these patients.

**Methods:** A total of 19 patients with mutations in BTK gene were analyzed for the expression and phosphorylation of BTK protein through immunoblotting. The correlations between BTK expression and the results of immunoblotting as well as clinical and immunologic phenotypes were evaluated.

**Results:** Six patients showed normal expression of protein and phosphorylation of BTK and two patients had normal phosphorylation while no expression was observed. There was a significant difference between the groups of patients with normal expression of protein and those without it ( $p=0.01$ ).

**Conclusions:** Since we identified 6 patients with normal expression and phosphorylation of BTK, and two patients with normal phosphorylation but no expression, thus more studies should be done in order to explore other aspects of the disease. Although there was not any significant correlation between the severity of clinical manifestations and BTK expression, further investigations are necessary to determine the compensatory mechanisms in XLA patients.

**Keywords** X-linked agammaglobulinemia, Bruton's tyrosine kinase, protein expression and phosphorylation.

\* **Corresponding author:** Fatemeh Kiaee

**E-mail:** fa\_kiaei@yahoo.com

1. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran

2. Department of Immunology, School of Public Health Tehran University of Medical Sciences Tehran, Iran

3. Department of Medical Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4. Medical Genetics Network (MeGeNe), Universal Scientific Education and Research Network (USERN), Tehran, Iran

¥ These authors are first authors in this work.

## Introduction

The most common group of primary immunodeficiency diseases (PIDs) are primary antibody deficiencies (PAD) in which affected patients have an early B cell defects causing agammaglobulinemia (1-3). As a prototype of agammaglobulinemias, XLA is a humoral immunodeficiency disorder manifesting with severe bacterial infections as a result of a significant reduction or absence of B cells and almost lack of all serum immunoglobulin isotypes (4-6). Newborns with XLA are normal in early postnatal months of their life due to the maternal antibodies transferred through the placenta. However, by the end of the half-life of the above-mentioned maternal antibodies, recurrent infections occur especially those of the respiratory and gastrointestinal tracts (7).

Impairments in the expression and function of Bruton's tyrosine kinase (BTK), a cytoplasmic kinase for B-cell receptor (BCR) downstream signaling crucial for B cells development, proliferation, and survival, cause XLA phenotype. (8, 9). X-linked pattern of inheritance makes the diagnosis of XLA likely where the early diagnosis of XLA is confirmed with the presence of mutations in *BTK* gene, resulting in defects in the expression and function of BTK protein (10). This gene contains 19 exons and encodes a multidomain protein composed of five different domains (11, 12). Over 1100 mutations in the genes encoding BTK have been identified in affected patients (13, 14).

The scientific methods applied to the clinical diagnosis are investigations of genomic mutations for *BTK* along with the assessment of the expression and function of BTK protein (15). Indeed, genetics and immunological approaches are robust in the definitive diagnosis of XLA (16). However, in most of the previous reports, the expression and function of the protein had not been analyzed (17). Applying methods such as exon sequencing can identify present mutations, yet detecting these mutations will not confirm the absence of *BTK* gene's expression; thus, studying BTK protein's expression in addition to its function is essential in providing insights into the diagnosis of XLA. The present study aimed to provide an informative outlook of clinical and immunological manifestations of XLA along with the evaluation of the expression and phosphorylation of BTK protein in patients with XLA. For studying the expression and function of proteins like BTK, flow cytometry and western blotting are amongst the valid methods for investigation (8, 18, 19). Here, western blotting was preferred for analysis of BTK protein since it has been considered to be gold standard in the detection and characterization of protein mixtures (20).

## Materials and methods

### Study population and ethical considerations

Twenty male subjects with an established diagnosis of primary agammaglobulinemia were enrolled in the study. Inclusion criteria were

designed according to the European Society of Immune Deficiencies (ESID) including very low circulating B cells (<2%) with a normal number of T cells, low level of serum IgG (200 mg/dl and 500 mg/dl in <12 and >12 months of age, respectively) with documented recurrent infections before 5 years of age (21). The procedure of this study was approved by the ethics committee of Tehran University of Medical Science (TUMS) and written informed consents were also obtained from both the adult patients and the children's parents.

### **Collection of data**

The data, obtained from our charts or a survey from reviewing patients' hospital records, included the following: personal information, family history, findings at diagnosis, clinical evolutions, and treatment.

### **Collection and preparation of samples**

Peripheral blood mononuclear cells (PBMCs) were prepared by collecting the lower band of Polymorphprep (Nycomed. Oslo, Norway) separation from the citrated whole blood. A total of  $10^7$  PMN cells were washed twice in phosphate buffer saline (PBS) and lysed in 1 mL of the cell lysis buffer (150 mM NaCl, 5 mM EDTA and 0.05% NP-40) for 5 min on ice. The obtained lysates were clarified via centrifugation in 18,000g for 10 min to be used for Western blot analysis.

### **Western Blot analysis of BTK expression and phosphorylation**

The supernatant of prepared lysate was incubated with 7 pL of anti-BTK antiserum (prepared by the same method as described by Tsukada *et al* (22)) on ice for 60 minutes which was followed by overnight incubation with conjugations of protein A sepharose beads at 4°C. The beads were then washed 4 times (2X with 1 mL of the cell lysis buffer). Finally, the samples were loaded onto a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Immobilon P: Millipore Corp, Bedford, MA). The membranes were processed as follows: blocking with 5% bovine serum albumin (BSA) in TBST (20 mmol/L Tris HCl [pH, 7.51], 150 mmol/L NaCl, and 0.05% Tween 20) for 1 hour, incubation with the hybridoma supernatant of 48-28 (diluted 1:s) for 1 hour, washing 3 times with TBST for 10 min each time. BTK was detected using the mAb 8F10 (provided by Dr D. L. Nelson, National Cancer Institute, National Institutes of Health), peroxidase goat anti-mouse as a secondary antibody (Sigma), and the ECL system (Amersham Biosciences, Buckinghamshire, United Kingdom). BTK autokinase capacity was also analyzed through immunoblotting with an anti-phospho-Tyr223-BTK antibody (Cell Signaling Technology, Beverly, Mass). Both protein extracts obtained from total PBMCs were used as controls; membranes were reblotted with anti-beta-actin (Sigma) to demonstrate equal loading.

### **Statistical analysis**

Statistical analyses were performed using the SPSS software package, version 22 (SPSS Inc., Chicago, IL, USA). Kolmogorov-Smirnov test was used to check the normality assumption for variables. Values were expressed as frequency (number and percentage), mean  $\pm$  standard deviation and median (interquartile range, IQR) where necessary. Fisher's exact test and chi-square tests were used for  $2 \times 2$  comparison of categorical variables, while t-tests, one-way ANOVA and their nonparametric equivalent were used to compare numerical variables.

## Results

In total, 20 subjects from 13 unrelated families with a median age of 22.0 (16-29) years were enrolled in the present study. One patient was excluded since the lysed sample of their blood was not obtained. Demographic and immunological characteristics of the patients are summarized in **Table 1**. The median age of diagnostic delay was 5 years and the patients were followed up for a median period of 17 years. Also, 11 (57%) of the patients had a family history of XLA. Almost all of the subjects experienced recurrent infections during the follow-up time where otitis media, pneumonia, and recurrent diarrhea were the most common complications. As shown in **Figure 1**, 6 patients showed normal expression of protein and phosphorylation of BTK including P1, P6, P7, P15, P16, and P19 patients. Two patients (P5 and P12) had normal

phosphorylation while no expression was observed and there was a significant difference between the two groups of patients with normal expression of protein and those without it ( $p=0.01$ ). Patients who had no BTK phosphorylation have not been shown.

None of the immunological findings showed any significant differences with BTK expression in XLA cases as compared to those without expression of BTK (**Table 1**). Age at onset of symptoms was not influenced by the type of *BTK* gene variation ( $p=0.4$ ) and there was no correlation between the immunoglobulin levels of IgG, IgA, as well as IgM serum and *BTK* expression ( $p=0.7$ ,  $p=0.1$  and  $p=0.3$ , respectively), while the occurrence of autoimmune disorders (1/13[7%] vs. 3/6[50%],  $P=0.07$ ) was higher in the patients with BTK expression than in those without. Further, the patients without BTK expression showed a tendency towards higher frequency of multiple organ infections (12/13[92%] vs. 3/6[50%],  $P=0.07$ ). However, the variation was not statistically significant.


Molecular genetic analysis was also performed for the patients the results of which are presented in **Table 3**. The most common mutation was a non-frameshift missense in the catalytic kinase (SH1) and pleckstrin homology (PH) domains in both groups. Nevertheless, no significant difference was found between the involved domains and the expression of BTK protein and phospho-BTK protein.

**Table 1.** Demographic and immunological data of patients with XLA

Parameters	Total (n=19)	BTK expression		p.value*
		NO (n=13)	Yes (n=6)	
Current age (Months), Mean (range)	273.5 (60.0-528.0)	302.8 (60.0-528.0)	210.0 (84.0-348.0)	0.17
Age of onset, Months (IQR)	12.0 (7.0-60.0)	12.0 (9.0-72.0)	7.0 (6.0-40.0)	0.42
Age at diagnosis (Months), Mean (range)	79.73 (10.0-264.0)	89.38 (10.0-264.0)	58.83 (12.0-168.0)	0.33
Diagnosis delay (Months), Mean (range)	41.00 (24.0-79.0)	56.15 (0.0-180.0)	39.83 (0.0-108.0)	0.49
Course of disease, Months (IQR)	244.7 (49.0-479.0)	269.5 (49.0-479.0)	191.0 (69.0-341.0)	0.23
Consanguinity, Number (%)	6 (31%)	3 (23.1%)	3 (50.0%)	0.32
Positive family history, Number (%)	11 (57%)	7 (53.8%)	4 (66.7%)	0.65
IgG, mg/dl (IQR)	120.0 (39.0-221.0)	120.0 (48.5-230.5)	99.0 (19.5-179.5)	0.765
IgA, mg/dl (IQR)	3.0 (0.0-9.25)	5.0 (0.0-8.0)	0.0 (0.0-29.5)	1.00
IgM, mg/dl (IQR)	18.0 (4.0-29.3)	17.0 (5.5-23.50)	30.0 (2.5-78.0)	0.39
CD <sub>3</sub> <sup>+</sup> %, Mean (range)	92.0 (81.8-94.0)	92.0 (78.0-94.0)	92.0 (91.0-94.0)	0.63
CD <sub>4</sub> <sup>+</sup> %, Mean (range)	44.3 (18.0-73.0)	41.2 (18.0-61.0)	52.4 (42.0-73.0)	0.13
CD <sub>8</sub> <sup>+</sup> %, Mean (range)	37.2 (1.0-61.0)	39.2 (1.0-61.0)	32.2 (8.0-47.0)	0.40
CD <sub>19</sub> <sup>+</sup> %, (IQR)	0.0 (0.0-2.0)	0.0 (0.0-0.0)	2.0 (0.0-2.0)	0.27
WBC *10 <sup>9</sup> /L, Mean (range)	10116 (3870-18000)	9583 (3870-16220)	11181 (6930-18000)	0.44
Lymphocytes (%), Mean (range)	41.1 (14.0-79.0)	42.0 (14.0-79.0)	39.3 (15.0-66.0)	0.79
Neutrophil (%), Mean (range)	48.6 (10.0-85.0)	48.1 (10.0-79.0)	49.5 (22.0-85.0)	0.90
Hb, g/dl (IQR)	12.0 (10.0-13.0)	13.0 (10.9-13.0)	11.0 (10.0-12.5)	0.41
BTK domain		0		
SH2 domain	1	7	1	0.50
PH domain	10	6	3	
SH1/TK domain	8		2	
BTK phosphorylation	8/19 (42%)	2/13 (15%)	6/6 (100%)	0.01*
Type of mutations				
Deletion	2	1	1	
Nonsense	3	3	0	0.08
Missense	9	4	5	
Splicing-site	5	5	0	

IQR: 25<sup>th</sup> to 75<sup>th</sup> inter quintile range.\**p-value* is statistically significant <0.05

WBC: White Blood Cell; HB: Hemoglobin; CD: Cluster of Differentiation

**Figure 1.** BTK expression (A), (B) and (C); BTK phosphorylation (D)

## Discussion

Bruton's disease, as the X-linked form of agammaglobulinemia, originates from the primary defect in the development of B lymphocytes causing hypogammaglobulinemia, a sharp decline in the number of peripheral B lymphocytes, reduced size of lymph nodes and tonsils along with recurrent bacterial infections (23). Mutations in *BTK* gene and consequently lack of the corresponding BTK protein or impairment in its function as the underlying causes, lead to the failure in the maturation of pre-B cells causing XLA (8, 24). Evaluating the expression and function of BTK protein was the subject of current study using western blot analysis along with the data from the hospital records of subjects including immunological, genetics, and clinical information in patients with the confirmed clinical diagnosis of XLA.

Mutational analysis results of the current study (**Table 1**) indicated that almost all of the nonsense and splice-site mutations which have been predicted to be severe were associated with null expression and function of BTK protein ( $p=0.08$ ). This is exactly consistent with the necessity of BTK's presence for activation of its downstream mechanisms in various pathways such as IKK and NF $\kappa$ B pathways as important signals for survival regulation, activation, growth, and proliferation of B cells (**Figure 2**) (25-28). Additionally, in the study conducted by Kanegane *et al.*, all of the patients with normal expression and function of BTK protein were reported to be diagnosed with mild predicted mutations (29). The observed BTK protein expression in 6 patients revealed that some mutations in domains had no effects on protein stability in these patients, while they may have led to the instability of the

protein in those patients without BTK expression. Weakly positive results for the functionality of BTK in these patients may suggest a variation in their domains that did not affect the kinase activity or the stability of altered proteins. Further, this may be indicative of a compensatory role of the Tec kinase for the detected protein (17), rather than its essential role as a regulatory factor in apoptosis and JNK/SAPK kinase activity (30). These are also in agreement with the results of Holinski-Feder *et al.* from immunoblotting analyses of cases with confirmed mutations in BTK (31). They reported lack of BTK expression in subjects with splice-site and nonsense mutations, while some of those with missense mutations

showed BTK expression and in some cases positive BTK kinase activity, using western blot analyses.


Investigations for genotype-phenotype correlation (**Table 2**) revealed almost a positive correlation between null BTK expression and autoimmunity manifestations along with multiple organ infections (both  $p=0.07$ ) in corresponding patients. These results are in concordance with the fact that less severe mutations with less detrimental effects on the expression and function of the BTK protein result in a higher percentage of B-cells and higher levels of immunoglobulins (32, 33) thus less infection and a lower probability to be affected by an autoimmune disorder (34, 35).

**Table 2.** Clinical features of the 19 XLA patients

Manifestations	Total (n=19)	BTK expression		p. value*
		NO (n=13)	Yes (n=6)	
<b>Respiratory tract infection, Number (%)</b>	15/19 (78%)	10/13 (76%)	5/6 (83%)	1.00
<b>Pneumonia, Number (%)</b>	11/19 (57%)	9/13 (69%)	2/6 (33%)	0.32
<b>Otitis media, Number (%)</b>	12/19 (63%)	8/13 (61%)	4/6 (66%)	1.00
<b>Bronchiectasis, Number (%)</b>	7/19 (36%)	5/13 (38%)	2/6 (33%)	1.00
<b>Clubbing of nails, Number (%)</b>	4/19 (21%)	2/13 (15%)	2/6 (33%)	0.55
<b>Sinusitis, Number (%)</b>	13/19 (68%)	9/13 (69%)	4/6 (66%)	1.00
<b>Enteropathy, Number (%)</b>	5/19 (26%)	4/13 (30%)	1/6 (16%)	0.63
<b>Lymph proliferation, Number (%)</b>	2/19 (10.5%)	1/13 (7%)	1/6 (16%)	1.0
<b>Recurrent diarrhea, Number (%)</b>	7/19 (36%)	6/13 (46%)	1/6 (0.16%)	0.33
<b>Autoimmune, Number (%)</b>	4/19 (21%)	1/13 (7%)	3/6 (50%)	0.07
<b>Gastrointestinal, Number (%)</b>	7/19 (36%)	6/13 (46%)	1/6 (16%)	0.33
<b>Rheumatologic, Number (%)</b>	9/19 (47%)	7/13 (53%)	2/6 (33%)	0.62
<b>Neurologic, Number (%)</b>	6/19 (31%)	6/13 (46%)	0/6 (0.0%)	0.10
<b>Dermatologic, Number (%)</b>	6/19 (31%)	4/13 (30%)	2/6 (33%)	1.00
<b>Multiple organ infections, Number (%)</b>	15/19 (78%)	12/13 (92%)	3/6 (50%)	0.07

\*p-value is statistically significant <0.05

**Figure 2.** BTK is involved in multiple signal-transduction pathways including survival regulation, activation, proliferation, and differentiation of B-lineage lymphoid cells. Initiation of BCR signaling involves LYN and SYK, part of the Src family. LYN phosphorylates the intracellular domain of the BCR, leading to the recruitment and phosphorylation of SYK. Activated SYK then phosphorylates the adaptor protein SLP65 (BLNK), which results in the recruitment of BTK and its phosphorylation by SYK at Tyr551. BTK, in turn, becomes autophosphorylated at Tyr223 for its full activation, and then phosphorylates PLC- $\gamma$ 2. LYN also activates the BCR co-receptor CD19, leading to the activation of the PI3K/AKT pathway, which is responsible for B-cell differentiation, survival, and proliferation



In a study by Abolhassani et al, the level of protein expression was evaluated in 27 patients with XLA including 12 patients of our study using flowcytometry (14). As reported in **Table 3**, our results are similar to their findings except for 2 patients (P1 and P5). This discrepancy can be explained due to use of different antibodies which recognize distinct epitopes of BTK. Indeed, the monoclonal anti-BTK antibody used in the current study have been declared to be produced by immunizing rabbits with a synthetic peptide corresponding

to residues surrounding Asp195 of human Btk protein while the anti-BTK antibody used in the abovementioned study may be bounded to other residues. Further, the reported normal kinetic function of the protein can be attributed to the presence of monocytes in the prepared lysate in our study. Teimourian *et al.* investigated the expression of BTK using flow cytometry in 22 subjects including P5 of the present study and reported normal BTK expression in contrast to null BTK expression in our study. This can be explained regarding



possible false positive results of flow cytometry (36). Also, normal phosphorylation with no BTK expression in P5 and P12 may be due to Phospho-Btk (Tyr223) mAb which recognizes Btk protein only when it is phosphorylated at Tyr223 within the SH3 domain, while Btk mAb recognizes total Btk protein.

However, the data of our study are almost in concordance with the results of another study by Lopez-Herrera et al. They found BTK expression in 21.4% of subjects with XLA. Specifically, they investigated the mutations in BTK gene and expression of BTK protein in 14 patients with clinical and immunological criteria of ESID for XLA using both western blotting and flow cytometry (37). Western blot analysis demonstrated very low expression of BTK only in three subjects with XLA, while flowcytometry of monocytes showed a low mean fluorescent intensity (MFI) for most of the subjects with XLA. In this regard, Kanegane et al. investigated hypogammaglobulinemic males through flowcytometric analysis of BTK protein expression in monocytes and genetic analyses of related BTK gene (29). Their observed less BTK expression in 88% of subjects with confirmed mutations for BTK as compared to normal healthy subjects. In another study, Tani et al. employed flowcytometric analyses of BTK expression on 16 Brazilian males with confirmed mutations of BTK causing XLA; 13

subjects (81.2%) showed a complete form of BTK deficiency (38). It can be concluded that these findings suggest more consistency for results of genetic studies with the findings of Western blot analysis of proteins and this technique is superior to flow cytometry for tracking BTK protein.

On the other hand, P10 and P13, P15, and P19, as three distinct groups of patients from the same families showed different clinical manifestations despite the same mutations. P10 and P15 had Hodgkin's lymphoma and Kawasaki disease, respectively, while another member of their family, P13 and P19, did not manifest the same complication suggesting that patients from the same family with the same mutations are not similar concerning the disease severity, and other different mechanisms are involved in the course of the disease which are yet to be identified.

It can be concluded that, although some patients have normal BTK protein expression without BTK protein phosphorylation, there are some patients who have both normal BTK protein expression and phosphorylation. So, it is necessary to determine which protein domain is involved in these patients. Further, western blotting using different anti-BTK antibodies would be more beneficial for the detection of different defective binding sites, though confirmation of relative gene defects using mutational analyses is required.

**Table 3.** Genetic and analysis in subjects with XLA

Patient	Domain	Mutation	Variation type	BTK exp(WB)	PBTK exp	BTK exp (flow)
1	SH2	c.906_908 del AGG	Small in-frame deletion	N	N	UN
2	PH	c.178_180 del AAG	Small in-frame deletion	NU	NU	ND
3	SH1/TK	ivs15-13 del TTG	Frameshift nonsense	NU	NU	UN
4	PH	c.110 T<C	Non-frameshift missense	NU	NU	ND
5	SH1/TK	c.1978 C<T	Non-frameshift missense	NU	N	N
6	PH	c.214 C<T	Non-frameshift missense	N	N	ND
7	PH	c.214 C<T	Non-frameshift missense	N	N	ND
8	PH	c.31+5G<C	Splice-site	NU	NU	ND
9	SH1/TK	ivs14-1G>A*	Splice-site	NU	NU	UN
10	SH1/TK	c.1922G<A	Non-frameshift missense	NU	NU	ND
11	PH	ivs1+5G<C*	Splice-site	NU	NU	UN
12	PH	ivs1+5 G<C*	Splice-site	NU	N	UN
13	SH1/TK	c.1922G<A	Non-frameshift missense	NU	NU	ND
14	PH	c.349 del A	Frameshift nonsense	NU	NU	N
15	SH1/TK	c.1651T<C	Non-frameshift missense	N	N	UN
16	PH	c.214 C<T	Non-frameshift missense	N	N	UN
17	SH1/TK	c.1896 G<A	Non-frameshift nonsense	NU	NU	N
18	PH	ivs3+2 T>C	Splice-site	NU	NU	N
19	SH1/TK	c.1651T<C	Non-frameshift missense	N	N	UN

**Conflict of interest**

The authors declare no conflict of interest.

**Acknowledgments**

We are grateful to the entire staff in the Immunology Department

**References**

1. Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. *Journal of clinical immunology*. 2013 Jan;33(1):1-7. PubMed PMID: 22847546.
2. Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. *Mayo Clinic proceedings*. 2009;84(1):16-22. PubMed PMID: 19121249. Pubmed Central PMCID: 2630110.

3. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. *Journal of clinical immunology*. 2007 Sep;27(5):497-502. PubMed PMID: 17577648.

4. Vihinen M, Brandau O, Branden LJ, Kwan SP, Lappalainen I, Lester T, et al. BTKbase, mutation database for X-linked agammaglobulinemia (XLA). *Nucleic acids research*. 1998 Jan 01;26(1):242-7. PubMed PMID: 9399844. Pubmed Central PMCID: 147244.

5. Graziani S, Di Matteo G, Benini L, Di Cesare S, Chiriaco M, Chini L, et al. Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells: XLA diagnosis or not? *Clinical immunology*. 2008 Sep;128(3):322-8. PubMed PMID: 18708023.

6. Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. *Clinical*,

- immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. *Clinical immunology*. 2002 Sep;104(3):221-30. PubMed PMID: 12217331.
7. Pac M, Bernatowska EA, Kierkus J, Ryzko JP, Cielecka-Kuszyk J, Jackowska T, et al. Gastrointestinal disorders next to respiratory infections as leading symptoms of X-linked agammaglobulinemia in children - 34-year experience of a single center. *Archives of medical science : AMS*. 2017 Mar 1;13(2):412-7. PubMed PMID: 28261296. Pubmed Central PMCID: PMC5332446. Epub 2017/03/07. eng.
8. Gaspar HB, Lester T, Levinsky RJ, Kinnon C. Bruton's tyrosine kinase expression and activity in X-linked agammaglobulinaemia (XLA): the use of protein analysis as a diagnostic indicator of XLA. *Clinical and experimental immunology*. 1998 Feb;111(2):334-8. PubMed PMID: 9486400. Pubmed Central PMCID: 1904924.
9. Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. *Immunological reviews*. 2009 Mar;228(1):58-73. PubMed PMID: 19290921.
10. Aghamohammadi A, Fiorini M, Moin M, Parvaneh N, Teimourian S, Yeganeh M, et al. Clinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia. *International archives of allergy and immunology*. 2006;141(4):408-14. PubMed PMID: 16943681.
11. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. *Nature*. 1993 Jan 21;361(6409):226-33. PubMed PMID: 8380905. Epub 1993/01/21. eng.
12. Ohta Y, Haire RN, Litman RT, Fu SM, Nelson RP, Kratz J, et al. Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. *Proceedings of the National Academy of Sciences of the United States of America*. 1994 Sep 13;91(19):9062-6. PubMed PMID: 8090769. Pubmed Central PMCID: PMC44747. Epub 1994/09/13. eng.
13. Sediva A, Smith CI, Asplund AC, Hadac J, Janda A, Zeman J, et al. Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes. *Journal of clinical immunology*. 2007 Nov;27(6):640-6. PubMed PMID: 17851739.
14. Abolhassani H, Vitali M, Lougaris V, Giliani S, Parvaneh N, Parvaneh L, et al. Cohort of Iranian Patients with Congenital Agammaglobulinemia: Mutation Analysis and Novel Gene Defects. *Expert review of clinical immunology*. 2016;12(4):479-86. PubMed PMID: 26910880. Epub 2016/02/26. eng.
15. Lopez-Granados E, Perez de Diego R, Ferreira Cerdan A, Fontan Casariego G, Garcia Rodriguez MC. A genotype-phenotype correlation study in a group of 54 patients with X-linked

- agammaglobulinemia. *The Journal of allergy and clinical immunology*. 2005 Sep;116(3):690-7. PubMed PMID: 16159644.
16. Jefferies CA, Doyle S, Brunner C, Dunne A, Brint E, Wietek C, et al. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. *The Journal of biological chemistry*. 2003 Jul 11;278(28):26258-64. PubMed PMID: 12724322.
17. Broides A, Yang W, Conley ME. Genotype/phenotype correlations in X-linked agammaglobulinemia. *Clinical immunology*. 2006 Feb-Mar;118(2-3):195-200. PubMed PMID: 16297664.
18. Hashimoto S, Tsukada S, Matsushita M, Miyawaki T, Niida Y, Yachie A, et al. Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. *Blood*. 1996 Jul 15;88(2):561-73. PubMed PMID: 8695804.
19. Takashima T, Okamura M, Yeh TW, Okano T, Yamashita M, Tanaka K, et al. Multicolor Flow Cytometry for the Diagnosis of Primary Immunodeficiency Diseases. *Journal of clinical immunology*. 2017 Jun 08. PubMed PMID: 28597144.
20. Dsouza A, Scofield RH. Protein Stains to Detect Antigen on Membranes. *Methods in molecular biology*. 2015;1314:33-40. PubMed PMID: 26139252.
21. Grimbacher B, Party ERW. The European Society for Immunodeficiencies (ESID) registry 2014. *Clinical and experimental immunology*. 2014 Dec;178 Suppl 1:18-20. PubMed PMID: 25546747. Pubmed Central PMCID: 4285476.
22. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. *Cell*. 1993 Jan 29;72(2):279-90. PubMed PMID: 8425221. Epub 1993/01/29. eng.
23. Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. *Clinical reviews in allergy & immunology*. 2000 Oct;19(2):183-204. PubMed PMID: 11107501.
24. Conley ME, Broides A, Hernandez-Trujillo V, Howard V, Kanegane H, Miyawaki T, et al. Genetic analysis of patients with defects in early B-cell development. *Immunological reviews*. 2005 Feb;203:216-34. PubMed PMID: 15661032.
25. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America*. 1999 Aug 03;96(16):9136-41. PubMed PMID: 10430908. Pubmed Central PMCID: 17745.
26. Bendall HH, Sikes ML, Ballard DW, Oltz EM. An intact NF-kappa B signaling pathway is required for maintenance of mature B cell subsets. *Molecular immunology*. 1999 Feb;36(3):187-95. PubMed PMID: 10403484.

27. Grumont RJ, Rourke IJ, O'Reilly LA, Strasser A, Miyake K, Sha W, et al. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. *The Journal of experimental medicine*. 1998 Mar 02;187(5):663-74. PubMed PMID: 9480976. Pubmed Central PMCID: 2212175.
28. Kontgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D, et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. *Genes & development*. 1995 Aug 15;9(16):1965-77. PubMed PMID: 7649478.
29. Kanegane H, Futatani T, Wang Y, Nomura K, Shinozaki K, Matsukura H, et al. Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis. *The Journal of allergy and clinical immunology*. 2001 Dec;108(6):1012-20. PubMed PMID: 11742281.
30. Kawakami Y, Miura T, Bissonnette R, Hata D, Khan WN, Kitamura T, et al. Bruton's tyrosine kinase regulates apoptosis and JNK/SAPK kinase activity. *Proceedings of the National Academy of Sciences of the United States of America*. 1997 Apr 15;94(8):3938-42. PubMed PMID: 9108083. Pubmed Central PMCID: 20546.
31. Holinski-Feder E, Weiss M, Brandau O, Jedele KB, Nore B, Backesjo CM, et al. Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course. *Pediatrics*. 1998 Feb;101(2):276-84. PubMed PMID: 9445504.
32. Wood PM, Mayne A, Joyce H, Smith CI, Granoff DM, Kumararatne DS. A mutation in Bruton's tyrosine kinase as a cause of selective anti-polysaccharide antibody deficiency. *The Journal of pediatrics*. 2001 Jul;139(1):148-51. PubMed PMID: 11445810. Epub 2001/07/11. eng.
33. Noordzij JG, de Bruin-Versteeg S, Comans-Bitter WM, Hartwig NG, Hendriks RW, de Groot R, et al. Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children. *Pediatric research*. 2002 Feb;51(2):159-68. PubMed PMID: 11809909. Epub 2002/01/26. eng.
34. Cooke A. Infection and autoimmunity. *Blood cells, molecules & diseases*. 2009 Mar-Apr;42(2):105-7. PubMed PMID: 19027331. Epub 2008/11/26. eng.
35. Blackmore S, Hernandez J, Juda M, Ryder E, Freund GG, Johnson RW, et al. Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis. *Proceedings of the National Academy of Sciences of the United States of America*. 2017 Jul 25;114(30):E6107-E16. PubMed PMID: 28696309. Pubmed Central PMCID: PMC5544260. Epub 2017/07/12. eng.
36. Crompton E, Van Damme M, Duvillier H, Pieters K, Vermeesch M, Perez-Morga D, et al. Avoiding false positive antigen detection by flow

cytometry on blood cell derived microparticles:  
the importance of an appropriate negative control.

PloS one. 2015;10(5):e0127209. PubMed PMID:  
25978814. Pubmed Central PMCID: 4433223.

37. Lopez-Herrera G, Berron-Ruiz L, Mogica-  
Martinez D, Espinosa-Rosales F, Santos-  
Argumedo L. Characterization of Bruton's  
tyrosine kinase mutations in Mexican patients  
with X-linked agammaglobulinemia. *Molecular  
immunology*. 2008 Feb;45(4):1094-8. PubMed  
PMID: 17765309.

38. Tani SM, Wang Y, Kanegane H, Futatani T,  
Pinto J, Vilela MM, et al. Identification of  
mutations of Bruton's tyrosine kinase gene (BTK)  
in Brazilian patients with X-linked  
agammaglobulinemia. *Human mutation*. 2002  
Sep;20(3):235-6. PubMed PMID: 12204007.